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Microbial biofilms have great negative impacts on the world’s economy and pose serious
problems to industry, public health and medicine. The interest in the development of
new approaches for the prevention and treatment of bacterial adhesion and biofilm
formation has increased. Since, bacterial pathogens living in biofilm induce persistent
chronic infections due to the resistance to antibiotics and host immune system.
A viable approach should target adhesive properties without affecting bacterial vitality
in order to avoid the appearance of resistant mutants. Many bacteria secrete anti-
biofilm molecules that function in regulating biofilm architecture or mediating the
release of cells from it during the dispersal stage of biofilm life cycle. Cold-adapted
marine bacteria represent an untapped reservoir of biodiversity able to synthesize a
broad range of bioactive compounds, including anti-biofilm molecules. The anti-biofilm
activity of cell-free supernatants derived from sessile and planktonic cultures of cold-
adapted bacteria belonging to Pseudoalteromonas, Psychrobacter, and Psychromonas
species were tested against Staphylococcus aureus, Staphylococcus epidermidis, and
Pseudomonas aeruginosa strains. Reported results demonstrate that we have selected
supernatants, from cold-adapted marine bacteria, containing non-biocidal agents able
to destabilize biofilm matrix of all tested pathogens without killing cells. A preliminary
physico-chemical characterization of supernatants was also performed, and these
analyses highlighted the presence of molecules of different nature that act by inhibiting
biofilm formation. Some of them are also able to impair the initial attachment of the
bacterial cells to the surface, thus likely containing molecules acting as anti-biofilm
surfactant molecules. The described ability of cold-adapted bacteria to produce effective
anti-biofilm molecules paves the way to further characterization of the most promising
molecules and to test their use in combination with conventional antibiotics.
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INTRODUCTION
The great ability of bacteria to colonize new environments can
be linked, in most cases, to their capacity to develop a protective
architecture called bioﬁlm. The bioﬁlm lifestyle is associated
with a high tolerance to exogenous stress, and treatment of
bioﬁlms with antibiotics or other biocides is usually ineﬀective
at eradicating them (Hall-Stoodley and Stoodley, 2009). Bioﬁlm
formation is therefore a major problem in many ﬁelds, ranging
from the food industry to medicine (López et al., 2010; Høiby
et al., 2011). It is worth mentioning that, in medical settings,
bioﬁlms are the cause of persistent infections implicated in
80% or more of all microbial cases-releasing harmful toxins
and even obstructing indwelling catheters (Epstein et al.,
2012).
Staphylococci are recognized as the most frequent causes of
bioﬁlm-associated infections (Otto, 2008). Staphylococcus aureus
(S. aureus) is an opportunistic dangerous pathogen that can
cause serious diseases in humans, ranging from skin and soft
tissue infections to invasive infections of the bloodstream, heart,
lungs and other organs. A statistical study showed that 30% of
U.S. population was colonized by S. aureus (Nicholson et al.,
2013). In addition, 1.5% of U.S. population was found to be a
carrier of methicillin-resistant S. aureus (MRSA) that is a major
cause of healthcare-related infections, responsible for signiﬁcant
proportion of nosocomial infections worldwide. Recently in the
U.S., deaths from MRSA infections have surpassed those from
many other infectious diseases, including HIV/AIDS (Nicholson
et al., 2013).
Staphylococcus epidermidis, conventionally considered as a
commensal bacterium of human skin, it can cause signiﬁcant
problems when breaching the epithelial barrier, especially
during bioﬁlm-associated infection of indwelling medical devices
(Dohar et al., 2009; Rogers et al., 2009). Most diseases caused by
S. epidermidis are of a chronic character and occur as device-
related infections (such as intravascular catheter or prosthetic
joint infections) and/or their complications (Rogers et al., 2009).
Pseudomonas aeruginosa (P. aeruginosa) is an important
pathogen responsible for infections in patients who suﬀer from
respiratory diseases (Saxena et al., 2014) like cystic ﬁbrosis (CF).
Recurrent and chronic respiratory tract infections in CF patients
result in progressive lung damage and represent the primary
cause of morbidity and mortality. P. aeruginosa can cause hard
to treat life threatening infections due to its high resistance to
antibiotics and to the ability to form antibiotic tolerant bioﬁlms.
The development of anti-bioﬁlm strategies is therefore of
major interest and currently constitutes an important ﬁeld
of investigation in which non–biocidal molecules are highly
valuable to avoid the rapid appearance of escape mutants.
From another point of view, the bioﬁlm could be considered
as a source of novel drugs and holds great potential due to the
speciﬁc physical and chemical conditions of its ecosystem. For
example, the production of extracellular molecules that degrade
adhesive components in the bioﬁlm matrix is a basic mechanism
used in the biological competition between phylogenetically
diﬀerent bacteria (Brook, 1999; Wang et al., 2007, 2010). These
compounds often exhibit broad-spectrum bioﬁlm-inhibiting or
bioﬁlm-detaching activity when tested in vitro and their use in a
combination therapy with antibiotics could be of interest.
Marine bacteria are a resource of biologically active products
(Debbab et al., 2010). Cold-adapted marine bacteria represent
an untapped reservoir of biodiversity endowed with an
interesting chemical repertoire. A preliminary characterization
of molecules isolated from cold-adapted bacteria revealed that
these compounds display antimicrobial, anti-fouling and various
pharmaceutically relevant activities (Bowman, 2007). The ability
of Polar marine bacteria, belonging to diﬀerent genera/species,
to synthesize bioactive molecules might represent the results of
the selective pressure to which these bacteria are subjected. One
of the developed survival strategies may be represented by the
production of metabolites with anti-bioﬁlm activity, which might
be exploited to ﬁght the biological competition of other bacteria.
Recently, we observed that Antarctic marine bacterium
Pseudoalteromonas haloplanktis TAC125 produces and secretes
several compounds of biotechnological interest (Papaleo et al.,
2013), including molecules inhibiting the bioﬁlm of the human
pathogen S. epidermidis (Papa et al., 2013b; Parrilli et al., 2015).
This activity impairs bioﬁlm development and disaggregates the
mature bioﬁlm without aﬀecting bacterial viability, showing that
its action is speciﬁcally directed against bioﬁlm (Papa et al.,
2013b; Parrilli et al., 2015).
In this work we evaluated the anti-bioﬁlm activity
of supernatants derived from cultures of cold-adapted
bacteria belonging to Pseudoalteromonas, Psychrobacter, and
Psychromonas genera. Supernatants were obtained from bacterial
cultures made both in sessile and planktonic conditions. The
potential anti-bioﬁlm activity was tested on bacterial cultures of
P. aeruginosa PAO1, three diﬀerent strains of S. aureus and three
diﬀerent strains belonging S. epidermidis species. The results
obtained highlighted that several supernatants show anti-bioﬁlm
activity against most species analyzed. Preliminary evaluations
on the physico-chemical nature of the molecules responsible for
anti-bioﬁlm activity emphasized their diﬀerent nature.
MATERIALS AND METHODS
Bacterial Strains and Culture Conditions
Bacterial strains used in this work are listed in Table 1. Bacteria
were grown in Brain Heart Infusion broth (BHI, Oxoid, UK).
Bioﬁlm formation was assessed in static conditions. Planktonic
cultures were grown in ﬂasks under vigorous agitation (180 rpm).
Cold-adapted bacteria were grown at 15◦C, while staphylococci
and P. aeruginosa were grown at 37◦C.
Biofilm Formation of Polar Bacteria
Bioﬁlm formation of cold-adapted bacteria was obtained at 15◦C
in BHI (Oxoid, UK). The wells of a sterile 24-well ﬂat-bottomed
polystyrene plate were ﬁlled with 1 ml of BHI, and an opportune
dilution of bacterial culture in exponential growth phase (about
0.1 OD 600 nm) was added into each well. The plates were
aerobically incubated up to 96 h at 15◦C in static condition,
measuring bioﬁlm formation each 24 h. After the removal of
spent medium and of not adhered cells and rinsing with PBS,
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TABLE 1 | Strains used in this study.
Strain Origin Reference and/or
source
Pseudoalteromonas
haloplanktis TAA207
Antarctic sea watera
(marine sediment)
Liège collection
Pseudoalteromonas
haloplanktis TAE56
Antarctic sea watera
(algae necrosed
suspended in sea water)
Liège collection
Pseudoalteromonas
haloplanktis TAE57
Antarctic sea watera
(algae necrosed
suspended in sea water)
Liège collection
Pseudoalteromonas
haloplanktis TAE79
Antarctic sea watera
(algae necrosed
suspended in sea water)
Liège collection
Pseudoalteromonas
haloplanktis TAE80
Antarctic sea watera
(algae necrosed
suspended in sea water)
Liège collection
Psychrobacter sp.TAD1 Antarctic sea watera Liège collection
Psychrobacter sp.TAD18 Antarctic sea watera
(frozen algae)
Liège collection
Pseudoalteromonas
haloplanktis TAB87
Antarctic sea watera Liège collection
Psychrobacter arcticus
273-4
Siberian permafrost
sediment cores
Bakermans et al., 2006
Psychromonas arctica Arctic seawater (Svalbard
islands, Arctic)
Groudieva et al., 2003
Staphylococcus aureus
6538P
Clinical isolate ATCC collection
Staphylococcus aureus
25923
Clinical isolate ATCC collection
Staphylococcus aureus
20372
Clinical isolate from septic
arthritis
ATCC collection
Staphylococcus
epidermidis RP62A
Reference strain isolated
from infected catheter
ATCC collection
Staphylococcus
epidermidis O-47
Clinical isolate from septic
arthritis
Heilmann et al., 1996
Staphylococcus
epidermidis XX-17
Clinical isolate from
infected catheter
Our collection
Pseudomonas aeruginosa
PAO1
Clinical isolate from wound ATCC collection
a Isolated from Antarctic coastal sea water sample collected in the vicinity of the
French Antarctic station Dumont d’Urville, Terre Adélie (66◦40′ S; 140◦ 01′ E).
adhered cells were stained with 0.1% crystal violet, rinsed twice
with double-distilled water, and thoroughly dried as previously
described (Papa et al., 2013a). The dye bound to adherent cells
was solubilized with 20% (v/v) glacial acetic acid and 80% (v/v)
ethanol. The absorbance of each well was measured at 590 nm.
Each data point is composed of four independent experiments
performed in triplicate.
Preparation of Cell-free Supernatants
from Cold-adapted Bacteria
The cell-free supernatants of a liquid culture of cold-adapted
strains grown in sessile condition were designated as SNB, while
the cell-free supernatants of a liquid culture of psychrophilic
strains grown in planktonic condition were designated as SNP.
For the preparation of SNB, wells of a sterile 24-well ﬂat-
bottomed polystyrene plate were ﬁlled with 900 µl of BHI and
100 µl of each overnight bacterial culture was added into each
well. The plates were incubated at 15◦C monitoring bioﬁlm
formation each 24 h. After 96 h, supernatants were recovered and
centrifuged at 13000 rpm at 4◦C for 30 min. Supernatants were
sterilized by ﬁltration through membranes with a pore diameter
of 0.22 µm, and stored at 4◦C until use.
For the preparation of SNP bacterial cultures were
grown in planktonic conditions at 15◦C under vigorous
agitation (180 rpm) for 24 h. Supernatants were recovered by
centrifugation at 13000 rpm at 4◦C and processed as described
above.
Biofilm Formation of Staphylococci and
Pseudomonas
Bioﬁlm formation of Staphylococcus and Pseudomonas species
was evaluated in the presence of SNB and SNP supernatants,
respectively. Quantiﬁcation of in vitro bioﬁlm production was
based onmethod previously reported (Artini et al., 2015). Brieﬂy,
the wells of a sterile 96-well ﬂat-bottomed polystyrene plate were
ﬁlled with 100 µl of the appropriate medium. 1/100 dilution of
overnight bacterial cultures was added into each well (about 5.0
OD 600 nm). Each well was ﬁlled with 50 µl of BHI and 50 µl of
each supernatant, respectively. In this way each supernatant was
used diluted 1:2 with a ﬁnal concentration of 50%. As control,
the ﬁrst row contained bacteria grown only in 100 µl of BHI
(untreated bacteria).The plates were incubated aerobically for
24 h at 37◦C.
Bioﬁlm formation was measured using crystal violet staining.
After treatment, planktonic cells were gently removed; each well
was washed three times with PBS and patted dry with a piece
of paper towel in an inverted position. To quantify bioﬁlm
formation, each well was stained with 0.1% crystal violet and
incubated for 15 min at room temperature, rinsed twice with
double-distilled water, and thoroughly dried. The dye bound to
adherent cells was solubilized with 20% (v/v) glacial acetic acid
and 80% (v/v) ethanol. After 30 min of incubation at room
temperature, OD590 was measured to quantify the total biomass
of bioﬁlm formed in each well. Each data point is composed
of three independent experiments each performed at least in
eight-replicates.
Surface Coating Assay
A volume of 25µl of cell-free supernatant (SNB or SNP), or 25µl
of saline as control, was deposited to the center of a well of a 24-
well tissue-culture-treated polystyrene microtiter plate. The plate
was incubated at 37◦C for 1 h to allow complete evaporation of
the liquid. The wells were then ﬁlled with 1ml of broth containing
104–105 CFU/ml of S. epidermidis O-47 and incubated at 37◦C.
After 18 h, wells were rinsed with water and stained with 1 ml of
0.1% crystal violet. Stained bioﬁlms were rinsed with water and
dried, and the wells were photographed.
Physico-chemical Characterization of
Anti-biofilm Compounds
The heat sensitivity of anti-bioﬁlm compounds were evaluated
by incubating the culture supernatants (SNB or SNP), for 1 h
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in a water bath at 50◦C and cooled on ice. For the protease
treatment, proteinase K (Sigma Aldrich, St Louis, MO, USA)
was added to aliquots of supernatants at a ﬁnal concentration
of 1 mg/ml and the reactions were incubated for 1 h at 37◦C.
As controls, supernatants were incubated for 1 h at 37◦C
without proteinase K, a treatment which did not impair the anti-
bioﬁlm activities. For each of the above tests, the anti-bioﬁlm
activities of treated and untreated culture supernatants were
compared using the microtiter plate assay against staphylococci
and P. aeruginosa PAO1, respectively. Each data point is
composed of three independent experiments performed in six-
replicates.
Statistics and Reproducibility of Results
Data reported were statistically validated using Student’s t-test
comparing mean absorbance of treated and untreated samples.
The signiﬁcance of diﬀerences between mean absorbance values
was calculated using a two-tailed Student’s t-test. A p-value of
<0.05 was considered signiﬁcant.
RESULTS
Cold-adapted Bacteria Biofilm Formation
Bioﬁlm formation of Polar bacteria was evaluated at 15◦C in BHI
at diﬀerent times as described in material and methods section.
Bacteria were grown in static condition in the same medium used
for staphylococci and P. aeruginosa cultures to avoid interference
in the following experiments due to the medium composition.
The bioﬁlm-forming ability of Polar bacterial strains was tested
by a quantitative assay. The best production of bioﬁlm was
obtained by incubating the cells in static condition for 96 h at
15◦C (data not shown). Almost all studied bacteria are able to
form bioﬁlm with diﬀerent capabilities (Table 2). For example,
in the tested condition, Pseudoalteromonas haloplanktis TAE80
and Psychrobacter arcticus 273-4 seemed to be unable to produce
bioﬁlm, while Psychromonas arctica was found to be a strong
bioﬁlm producer, as already reported (Vishnivetskaya et al., 2000;
Groudieva et al., 2003).
Effect of Exoproducts Derived from
Cold-adapted Cultures on Biofilm
Formation of Different Pathogen
The anti-bioﬁlm eﬀects of cold-adapted bacterial culture
supernatants grown at 15◦C either in planktonic or sessile
conditions were examined on diﬀerent pathogens: P. aeruginosa
PAO1, three strains belonging to S. epidermidis species, and three
strains belonging to S. aureus species (Table 1).
The speciﬁc environmental conditions prevailing within
bioﬁlms induce profound genetic and metabolic rewiring of
the bioﬁlm-dwelling bacteria and can allow the production
of metabolites diﬀerent from those obtained in planktonic
condition. Therefore, supernatants deriving from sessile growths
were designated as B letter, while supernatants deriving from
planktonic cultures under vigorous agitation were designated as
P letter, respectively.
TABLE 2 | Biofilm formation of the investigated bacterial strains.
Strain Biofilm (OD 590 nm)
TAA207 0.41 ± 0.09
Pseudoalteromonas haloplanktis TAE56 0.15 ± 0.06
Pseudoalteromonas haloplanktis TAE57 0.20 ± 0.10
Pseudoalteromonas haloplanktis TAE79 0.90 ± 0.20
Pseudoalteromonas haloplanktis TAE80 0.03 ± 0.02
Psychrobacter sp.TAD1 0.60 ± 0.20
Psychrobacter sp.TAD18 0.90 ± 0.20
Pseudoalteromonas haloplanktis TAB87 0.90 ± 0.20
Psychrobacter arcticus 273-4 0.09 ± 0.07
Psychromonas arctica 11.00 ± 1.00
Staphylococcus aureus 6538P 1.10 ± 0.10
Staphylococcus aureus 25923 1.90 ± 0.30
Staphylococcus aureus 20372 0.80 ± 0.20
Staphylococcus epidermidis RP62A 1.10 ± 0.10
Staphylococcus epidermidis O-47 2.10 ± 0.20
Staphylococcus epidermidis XX-17 0.69 ± 0.06
Psychrobacter aeruginosa PAO1 2.40 ± 0.50
Each data point is composed of four independent experiments performed in
triplicate. Standard errors are reported.
In order to exclude that the tested Polar supernatants
contain molecules aﬀecting bacterial viability, the 20 cell-
free supernatants were analyzed also for antimicrobial activity.
An opportune dilution (106 cfu/ml were used as reported by
National Committee for Clinical Laboratory Standards NCCLS,
2004) of each bacterial culture of S. aureus and P. aeruginosa
in exponential phase was seeded on TSA plates. Each plate was
spotted with Polar cell free supernatant separately and incubated
at 37◦C for 20 h. No antimicrobial activity on S. aureus and
P. aeruginosa strains was highlighted for all tested supernatants
(data not shown).
Anti-bioﬁlm eﬀect is reported as percentage of residual bioﬁlm
after treatment in comparison with untreated bacteria. In some
cases an increase of bioﬁlm formation was highlighted after the
treatment.
Several supernatants of Polar bacteria have anti-bioﬁlm
activity against all S. aureus tested strains (Figure 1,
Supplementary Table S1). S. aureus 6538P showed a reduction
in bioﬁlm formation when treated with cold-adapted bacteria
supernatants except in the case of TAA207 B and TAE80 P
supernatants. TAE80 and PSYA supernatants deriving from
both sessile and planktonic growth conditions showed a good
anti-bioﬁlm eﬀect on S. aureus 25923, a reference strain for CF
infections (Alhanout et al., 2011) (Figure 1). Three supernatants
(TAD1 B, TAD18 P, TAB87 P) allowed a reduction of S. aureus
20372 bioﬁlm higher than 50% (Figure 1). As shown in
Figure 1, supernatants derived from sessile and planktonic
cultures showed diﬀerences in their ability to prevent S. aureus
bioﬁlm formation and the eﬀect of each supernatant is strictly
strain-speciﬁc. Indeed, in such cases, the same supernatant
is able to impair bioﬁlm formation of one strain rather than
others belonging to the same bacterial species; for example,
TAD18 P is able to inhibit the bioﬁlm formation of S. aureus
6538P and S. aureus 20372 but it is of not eﬀective on S. aureus
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FIGURE 1 | Effect of Polar supernatant treatment on biofilm formation
for three strains of Staphylococcus aureus. Data are reported as
percentage of residual biofilm after the treatment. Biofilm formation was
considered unaffected in the range 90–100%. Differences in mean
absorbance were compared to the untreated control and considered
statistically significant when p < 0.05 (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001)
according to Student’s t-test.
25923. It is interesting to note that supernatants derived from
sessile and planktonic cultures of the same Polar bacterium
showed diﬀerences in their ability to prevent S. aureus bioﬁlm
formation, for example TAE80 B supernatant is able to impair
bioﬁlm of S. aureus 6538P while TAE80 P induces a signiﬁcant
increase in the bioﬁlm formation. In addition TAE79 B, but not
TAE79 P, produces an anti-bioﬁlm molecule able to inhibit the
bioﬁlm formation of S. aureus 25923. On the contrary TAE79
P treatment increases the bioﬁlm production of 25923 strain.
It is worth mentioning that one supernatant, i.e., TAD1 B, is
quite eﬀective in interfering with bioﬁlm formation of all tested
S. aureus strains.
As far as S. epidermidis is concerned (Figure 2), in most
cases the treatments induced an increase in bioﬁlm formation,
except for S. epidermidisO-47 strain treated with TAE79, TAE80,
TAD1, PSY273 and PSYA supernatants derived from planktonic
and sessile cultures where a strong reduction was evidenced
(Figure 2).
Also in the case of S. epidermidis, supernatants derived from
sessile and planktonic cultures of the same Polar bacterium
showed diﬀerences in their ability to prevent bioﬁlm formation.
Cell free supernatant of TAE56P is able to inhibit the bioﬁlm of
FIGURE 2 | Effect of Polar supernatant treatment on biofilm formation
for three strains of S. epidermidis. Data are reported as percentage of
residual biofilm after the treatment. Biofilm formation was considered
unaffected in the range 90–100%. Differences in mean absorbance were
compared to the untreated control and considered statistically significant
when p < 0.05 (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001) according to Student’s
t-test.
S. epidermidis O-47 while TAE56B has no eﬀect, indicating that
the anti-bioﬁlm molecule is produced only when the cells are
grown in planktonic condition.
Data reported in Figure 3 demonstrated that the ability
of P. aeruginosa PAO1 to form bioﬁlm is aﬀected by all
cold-adapted supernatants deriving from sessile cultures with
a rate of reduction between 30 and 50%. Only TAD1 P
is able to reduce the P. aeruginosa PAO1 bioﬁlm more
than 70%. An additional control experiment was performed
for P. aeruginosa in order to exclude a dilution eﬀect on
the bacterial growth after the supplementation with each
supernatant due to diverse nutrient concentration between
the untreated bacteria and the treated ones. In particular,
as growth medium was also used BHI 2X concentrated.
This experiment was performed in addition to the standard
condition because we noted an inhibitory eﬀect on bioﬁlm
formation when P. aeruginosa was treated with all supernatants.
Data obtained with BHI twofold concentrated were nearly
superimposable excluding an eﬀect due to the diverse nutrient
concentration between the treated and untreated bacteria (data
not shown).
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FIGURE 3 | Effect of Polar supernatant treatment on biofilm formation
for P. aeruginosa PAO1. Data are reported as percentage of residual biofilm
after the treatment. Biofilm formation was considered unaffected in the range
90–100%. Differences in mean absorbance were compared to the untreated
control and considered statistically significant when p < 0.05 (∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001) according to Student’s t-test.
Physico-chemical Characterization of
Anti-biofilm Compounds from Polar
Bacteria
To determine a preliminary chemical characterization of bioﬁlm-
inhibiting compounds, cell free supernatants of cold-adapted
bacteria were dispensed in several aliquots, and submitted to
chemical (proteinase K) and physical (thermal) treatments.
Percentage of bioﬁlm inhibition of each treated aliquot was
determined on S. epidermidis O-47, S. aureus 6538P and
P. aeruginosa PAO1 bioﬁlms (Table 3). Data are reported as the
percentage of anti-bioﬁlm activity remaining after each treatment
compared to the eﬀect of the same untreated supernatant. As
shown in Table 3, the proteinase K treatment reduced the anti-
bioﬁlm activity of tested supernatants on S. epidermidisO-47 and
S. aureus 6538P bioﬁlms, while this treatment did not interfere
with their anti-bioﬁlm ability on P. aeruginosa PAO1 except
for TAD18 B, indeed the proteinase K treatment reduced its
anti-bioﬁlm activity at value less than 10%.
Furthermore, thermal treatment at 50◦C signiﬁcantly reduced
the anti-bioﬁlm eﬀect of almost all supernatants on S. aureus but
did not impair their activity on P. aeruginosa and S. epidermidis.
This latter suggests that each supernatant contains diﬀerent
molecules with anti-bioﬁlm activity that works selectively and
independently on diﬀerent bacterial species.
Anti-biofilm Surfactant Activity of Polar
Compounds
To assess the ability of cell free Polar bacteria supernatants to
modify the surface properties of an abiotic substrate, a surface
coating assay was performed. Evaporation coating was used to
deposit each supernatant onto the surface of polystyrene wells,
and then the ability of the coated surfaces to repel bioﬁlm
formation by S. epidermidisO-47 was tested. This latter pathogen
was selected for this assay as it is the strongest bioﬁlm producer
amongst the bacteria used in this work and because it is able
to preferentially form bioﬁlm on the surface while P. aeruginosa
typically forms bioﬁlm at the liquid/air interface.
As clearly visible in Figure 4, TAE80 supernatants derived
from both planktonic and sessile cultures and TAD1 supernatant
derived from only sessile growth, were able to repel bioﬁlm
formation speciﬁcally only in the area where the supernatants
were deposited, indicating that they contain molecules acting as
anti-bioﬁlm surfactants.
DISCUSSION
In this paper the attention was focused on anti-bioﬁlm molecules
produced by cold-adapted marine bacteria since they represent
an untapped reservoir of biodiversity and a potential source
of molecules able to inhibit pathogens bioﬁlm formation. The
target pathogens chosen were P. aeruginosa, S. aureus, and
S. epidermidis.
Bioﬁlm is a key element in S. epidermidis, S. aureus, and
P. aeruginosa infectious processes, but the matrix composition
and molecules involved in attachment, development and
detachment phases in these three bacterial species, are very
diﬀerent (Joo and Otto, 2012). Further, pathways and regulation
of quorum sensing systems in these three strains are deeply
diﬀerent (Solano et al., 2014).
In staphylococci bioﬁlm formation depends on a complex
interplay of several elements such as adhesins, extracellular
matrix binding proteins, bioﬁlm associated proteins, proteins
involved in PIA synthesis (icaADBC), autolysins (Alt), etc.
Staphylococcus strains used in this work were chosen on the basis
of diﬀerent characteristics. In particular, S. aureusATCC 6538P is
a reference strain for antimicrobial testing; S. aureusATCC 25923
and ATCC 20372 are clinical isolates. As for their ability to form
bioﬁlm, S. aureus strains were classiﬁed as reported: ATCC 25923
is a strong bioﬁlm producer, ATCC 6538P is a medium/strong
bioﬁlm producer and ATCC 20372 is a medium/weak bioﬁlm
producer according to Caﬁso et al. (2007).
Several cold adapted bacteria produce molecules able to
interfere with S. aureus bioﬁlm formation. These molecules
display a diﬀerent eﬃciency on diﬀerent S. aureus tested strains
and in all strains the anti-bioﬁlm molecules seems to be
proteinaceous. On the contrary only few Polar strains produce
anti-bioﬁlm molecules active on S. epidermidis O-47 and RP62A
bioﬁlms, and none are able to interfere with S. epidermidis XX-
17 bioﬁlm formation. It is important to underline that XX-17
strain produces a bioﬁlm characterized by a polysaccharide ica-
independent poorly characterized so far.
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TABLE 3 | Effect of physico-chemical treatments on the anti-biofilm activity of cold-adapted bacteria supernatants on S. epidermidis O-47, S. aureus
6538P and P. aeruginosa PAO1, respectively.
Proteinase K treatment Heat treatment
S. epidermidis S. aureus P. aeruginosa S. epidermidis S. aureus P. aeruginosa
TAA207 P ND <10% 100% ND <10% 100%
TAE56 P <10% <10% ND 90%NS <10% ND
TAE57 P <10% <10% 80%∗∗ 100% <10% 100%
TAE79 P <10% <10% 85%∗∗ 100% <10% 100%
TAE80 P <10% ND 70%∗∗∗ 100% ND 100%
TAD1 P <10% <10% 85%∗∗ 80% <10% 100%
TAD18 P ND <10% ND ND <10% ND
TAB87 P ND <10% ND ND <10% ND
PSY273 P <10% <10% ND 90%NS <10% ND
PSYA P <10% ND 100% 90%NS ND 100%
TAA207 B ND ND 100% ND ND 90%NS
TAE56 B ND <10% 100% ND 40% 100%
TAE57 B ND <10% 70% ND <10% 100%
TAE79 B <10% <10% 80% 80%∗ <10% 100%
TAE80 B <10% <10% 100% 90%NS <10% 100%
TAD1 B <10% <10% 100% 60%∗∗ <10% 100%
TAD18 B ND <10% <10% ND 50% 100%
TAB87 B ND <10% 80%NS ND <10% 100%
PSY273 B <10% <10% 70%∗∗ 100% <10% 100%
PSYA B <10% ND 100% 100% ND 100%
With P letter was designated the cell-free supernatants of cold-adapted strains grown in planktonic condition; with B letter was designated the cell-free supernatants of
cold-adapted strains grown in sessile condition. Data are reported as percentage of residual activity compared with each untreated supernatant. Differences in mean
absorbance were compared to the untreated control and considerend significant when p < 0.05 (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; NS, Not Significant) according to
Student’s t-test. ND, not determined.
FIGURE 4 | Analysis of surfactant capability of each Polar supernatant on S. epidermidis O-47. The center of each well of a 24-well tissue-culture-treated
polystyrene microtiter plate was coated with each supernatant. After evaporation, the wells were then filled with staphylococci and incubated at 37◦C.
Then wells were rinsed with water and stained with 1 ml of 0.1% crystal violet. Stained biofilms were rinsed with water and dried, and the wells were photographed.
(A) Supernatants derived from planktonic growths. (B) Supernatants derived from biofilm growths.
Staphylococcus epidermidisRP62A is a reference strain isolated
from infected catheter; S. epidermidisXX-17 andO-47 are clinical
isolates. The clinical isolate O-47 is a naturally occurring non-
functional agr mutant characterized by a frameshift mutation
within agrC (Vuong et al., 2003) while the S. epidermidis XX-
17 is an ica defective mutant (Artini et al., 2013). Determination
of S. epidermidis bioﬁlm formation showed a strong production
for the O-47 strain, medium/strong production for the reference
strain RP62A and a medium/weak bioﬁlm formation for the XX-
17 strain deﬁned according to the literature (Caﬁso et al., 2004).
Moreover, the six staphylococcal strains considered here were
previously investigated to assess the presence of genes coding
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for various proteins involved in adhesion and bioﬁlm formation
(Artini et al., 2013).
In P. aeruginosa the bioﬁlm matrix is totally diﬀerent,
because the bacterium produces three exopolysaccharides, the
glucose-rich Pel polysaccharide (Friedman and Kolter, 2004),
the mannose-rich Psl polysaccharide (Friedman and Kolter,
2004), and alginate (Govan and Deretic, 1996). In particular, for
P. aeruginosawe used the reference strain PAO1 since the bioﬁlm
characterization of this strain was previously reported (Yang et al.,
2005).
The reported diﬀerences in bioﬁlm features of the three
pathogens could explain the diﬀerent ability of cold adapted
bacteria supernatants to impair their bioﬁlm formation. It is
interesting to note that, in all reported cases, the supernatants
proved to be non-biocidal and speciﬁcally directed against
bioﬁlm.
All studied Polar strains are able to produce anti-bioﬁlm
molecules against P. aeruginosa bioﬁlm. Furthermore in all cases
the anti-bioﬁlm molecules seems to have the same chemical-
physical features (were not heat-labile and seem to have a non-
protein nature), except in case of TAD18 B. These results could
suggest that the molecule responsible for the anti-bioﬁlm activity
is the same for all cold-adapted strains. In particular, Polar anti-
bioﬁlm molecules involved in the inhibition of P. aeruginosa
bioﬁlm could be polysaccharides or a small molecule acting
as quorum sensing inhibitors. Several studies have identiﬁed
diﬀerent bacterial polysaccharides and signaling molecules that
inhibit bioﬁlm formation by wide spectrum of bacteria including
P. aeruginosa (Valle et al., 2006; Wittschier et al., 2007; Kim et al.,
2009).
The increase of bioﬁlm production following the treatment
with such supernatants is an interesting result. This latter
strengthens the hypothesis regarding the production of
bacterial molecules able to regulate the bioﬁlm formation
inter- and intra- species in diﬀerent environmental niches.
The regulatory pathways of this phenotype could be linked to
competition dynamics of extreme habitats (i.e., Polar niches).
The identiﬁcation of the molecules responsible for these
mechanisms could be interesting and also open new perspectives
for the control of bacterial bioﬁlm formation. It is worth to
note that “row” supernatants that we used represent a complex
pool of chemical cues that could be characterized by diﬀerent
capabilities either responsible for impair bioﬁlm formation and
increase it.
Data reported in this paper demonstrate that anti-bioﬁlm
activity of cold-adapted bacteria supernatants deriving from
planktonic and sessile cell cultures display several diﬀerences
in terms of speciﬁcity and eﬃciency. Some bioﬁlm-speciﬁc
metabolites previously reported (Gjersing et al., 2007; Booth
et al., 2011; Yeom et al., 2013) may exhibit an antagonist
eﬀect against competing microorganisms. Indeed, several studies
showed that bacterial bioﬁlm constitute untapped sources of
natural bioactive molecules antagonizing adhesion or bioﬁlm
formation of other bacteria (Papa et al., 2013b; Rendueles et al.,
2013). Furthermore, diﬀerences between activity of supernatants,
derived from sessile and planktonic cultures, could be linked to a
diﬀerent concentration of active molecules produced in these two
growth conditions. This latter could be particularly relevant if the
active molecules are involved in quorum sensing signaling.
Moreover, in this paper we report that several cold-
adapted strains (TAD1, TAE79, TAE80, PSY273 and PSYA),
belonging to diﬀerent genera, are able to produce diﬀerent anti-
bioﬁlm molecules active against S. epidermidis, S. aureus and
P. aeruginosa bioﬁlms.
The preliminary chemical characterization of the anti-
bioﬁlm molecules indicates that the same bacterium produces
diﬀerent molecules active against diﬀerent targets. For
example, TAD1 produces a thermo-stable protein active
against S. epidermidis bioﬁlm, a thermo-labile protein
active against S. aureus bioﬁlm, and a non-proteinaceus
molecule able to impair P. aeruginosa bioﬁlm. Furthermore
the supernatants of TAD1 deriving from bioﬁlm and
planktonic growth showed also a diﬀerent behavior in
surface coating assay, suggesting the production of an anti-
bioﬁlm surfactant molecule only when TAD1 is grown in
sessile form. Also for the supernatants deriving from TAE80
growths were evidenced the presence of diﬀerent anti-bioﬁlm
molecules that are able to speciﬁcally act against the diﬀerent
bacterial species tested. In particular, we analyzed the dose
dependent proﬁle of TAE80 supernatants deriving form
planktonic and bioﬁlm growths tested against strongest
bioﬁlm producers belonging the three diﬀerent species
(Supplementary Figure S1). Both TAE80 supernatants (TAE80B
and TAE80P) showed an anti-bioﬁlm activity clearly dose-
dependent against S. aureus 25923 and S. epidermidis O-47
while their activity against P. aeruginosa does not seem to be
dose-dependent.
The ability of cold-adapted marine bacteria to produce
several anti-bioﬁlm molecules could suggest that the capacity
to avoid the bioﬁlm and colonization of competitor bacteria
is a selective advantage in this extreme environment. Besides
their ecological meaning, the anti-bioﬁlm molecules from cold-
adapted bacteria may have interesting biomedical applications
combined with conventional antibiotics in order to eradicate
bioﬁlm infection.
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